Catalyst Bullish Stance Reiterated At Roth Capital Following 2Q14 Results
In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on shares of Catalyst Pharmaceutical (CPRX) with a $3.50 price target, following the company’s second-quarter results. CPRX reported 2Q14 EPS of a $0.05 loss, which was lower than Henry’s targeted loss of $0.08.
Henry noted, “Fundamentally, we viewed the quarter as in-line. We reiterate our Buy rating for the promise of the Firdapse program for the treatment of LEMS with key clinical data likely in late 3Q14.” The analyst continued, “We continue to expect CPRX to bring about the first approved treatment for LEMS (ahead of Jacobus, although this entails risk). We further believe that shares are undervalued based on our approval probability assumption of 65%. The major catalyst for CPRX shares appears clinical data for Firdapse in late 3Q14. Investors should recognize the binary nature of clinical risk around the data release in 3Q14.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 21.1% and a 47.4% success rate. Henry has a -8.0% average return when recommending CPRX, and is ranked #209 out of 3242 analysts.